Since most dominant human mutations are single nucleotide substitutions 1,2 , we explored gene editing strategies to disrupt dominant mutations efficiently and selectively without affecting wild-type alleles. However, single nucleotide discrimination can be difficult to achieve 3 because commonly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to seven mismatches between guide RNA (gRNA) and target DNA. Furthermore, the protospacer-adjacent motif (PAM) in some Cas9 enzymes can tolerate mismatches with the target DNA 3,4 . To circumvent these limitations, we screened 14 Cas9/gRNA combinations for specific and efficient disruption of a nucleotide substitution that causes the dominant progressive hearing loss, DFNA36. As a model for DFNA36, we used Beethoven mice 5
, which harbor a point mutation in Tmc1, a gene required for hearing that encodes a pore-forming subunit of mechanosensory transduction channels in inner-ear hair cells 6 . We identified a PAM variant of Staphylococcus aureus Cas9 (SaCas9-KKH) that selectively and efficiently disrupted the mutant allele, but not the wild-type Tmc1/TMC1 allele, in Beethoven mice and in a DFNA36 human cell line. Adeno-associated virus (AAV)-mediated SaCas9-KKH delivery prevented deafness in Beethoven mice up to one year post injection. Analysis of current ClinVar entries revealed that ~21% of dominant human mutations could be targeted using a similar approach.
To increase specificity of gene editing, truncated gRNAs 7 or high-fidelity Cas9 variants [8] [9] [10] have been developed. To expand the targeting range of Cas9, variants that recognize different PAM sites have also been engineered 11, 12 . The possibility that the PAM sequence itself could distinguish mutant from wild-type alleles has been suggested 13, 14 , but the strategy has not been tested in vivo to ameliorate a disease phenotype.
We sought to develop allele-specific genome editing strategies for dominant hearing loss and focused on the Beethoven (Bth) mouse, an excellent model for DFNA36 hearing loss in humans 5 . The Bth mutation (c.T1253A) results in an amino acid substitution (p.M412K) in TMC1. The mutation causes hair cell degeneration and progressive hearing loss in mice. In humans, the p.M418K substitution is identical to the Bth mutation in the orthologous position and causes DFNA36, a dominant progressive hearing loss 15 . A recent study with cationic lipid delivery of Cas9-gRNA ribonucleoprotein complexes into the inner ears of Bth mice showed modest improvement in hearing thresholds 4 weeks after treatment 16 . However, the effect was not sustained and cellular degeneration was not halted, perhaps because the strategy did not selectively or efficiently target the mutant allele.
To selectively disrupt the Bth allele in fibroblasts from Tmc1
Bth/WT mice (Tmc1 WT/WT cells were used as controls), we screened various Cas9 and gRNA combinations in vitro. We tested SpCas9 in combination with 12 different gRNAs, including full-length and truncated forms targeting either Tmc1
Bth or Tmc1 WT (Extended Data Fig. 1 ). However, none of the various combinations, including the Cas9-gRNA combination previously reported to show transient improvement in auditory thresholds in Bth mice 16 (gRNA 1.1 in our study), had the necessary specificity, as indel formation was evident in both Bth and wild-type (WT) alleles (Extended Data Fig. 1 , Supplementary Data Sets 1 and 2). To improve allele selectivity, we evaluated high-fidelity SpCas9 enzymes; however none mediated selective targeting of the Bth allele (Fig. 1a ,b, Supplementary Data Set 3 and Extended Data Fig. 2) .
Next, we reasoned that a Cas9 nuclease with a PAM site selective for the mutant sequence might show specific targeting of the Tmc1 Bth allele. The Bth mutation is a T to A change; thus, the GGAAGT sequence present in Tmc1 Bth 
, but not in Tmc1
WT (GGATGT), may allow the PAM site of the SaCas9-KKH variant 11 (NNNRRT) to distinguish the Tmc1
Bth from the Tmc1 WT allele. We designed full-length and truncated gRNAs (Fig. 1a) and transfected plasmids expressing each of these together with SaCas9-KKH into fibroblasts. SaCas9-KKH induced indels only in Tmc1 Bth Bth/WT cells were present just in the mutant allele. The indel profile revealed that the Letters NATuRE MEDiCiNE majority of CRISPR-induced variants were deletions, the most common being a single base deletion causing a frame shift (Fig. 1d-f and Supplementary Data Set 3). Single nucleotide changes were not frequent events and were not different between Cas9-treated and control cells (Extended Data Fig. 3 ). The few indels (less than 0.2%) in Tmc1
WT/WT fibroblasts were not significantly different from 
Fig. 1 | targeting Tmc1
Bth allele with high-fidelity SpCas9s and SaCas9-KKH. a, gRNA design. The mutation site is highlighted in red. PAM sites are marked by green nucleotides. Mismatching nucleotides are shown in blue. SaCas9-KKH: KKH PAM variant of SaCas9, eSpCas9(1.1), HypaCas9 and SpCas9-HF1 are different high-fidelity variants of SpCas9 (used in combination with 1.1 gRNA, the same as in Extended Data Fig. 1a) . b, Indel percentage (mean) in Tmc1
Bth/WT and Tmc1 WT/WT fibroblasts determined by targeted deep sequencing and analysis using the computational tool CRISPResso. SpCas9 with 1.1, 2.1 and 2.4 gRNA represent the same conditions as in Extended Data Fig. 1 (except that cells were not sorted for GFP expression); however experiments were repeated to allow for head-to-head comparison with SaCas9-KKH and high-fidelity SpCas9 enzymes. Cells were transfected with SpCas9 (two occasions) or SpCas9 + gRNA 1.1 (four occasions) and genomic DNA from two independent biological samples on each transfection day were pooled for sequencing. c, Allele-specific indel analysis (mean) of the samples from b in Tmc1
Bth/WT cells. Tmc1 Bth and Tmc1 WT reads were segregated using a Python script and indel percentages were analyzed for each allele. Thus, one condition represents indel formation in the same population of cells. The numbers above the graphs show specificity towards the Beethoven allele, expressed as percentages. d, The most abundant reads in the SaCas9-KKH + gRNA 4.2 treated cells, shown separately for Tmc1
Bth (top) and Tmc1 WT (bottom) reads. The CRISPR cut site is marked by a black dashed line. Dashes represent deleted nucleotides. Nucleotides in bold are substitutions; however, these were not quantified as CRISPR actions. Sequences were aligned to Bth allele; thus, in the bottom panel, WT sequence appears as a substitution (an A to T change). The mutation site is marked by a red arrow. e, Indel profiles from SaCas9-KKH + gRNA 4.2 transfected Tmc1
Bth/WT fibroblasts. Tmc1 Bth and Tmc1 WT reads are plotted separately. Minus numbers represent deletions, plus numbers represent insertions. Sequences without indels (value = 0) are omitted from the chart. f, Indels causing in-frame versus frame-shift mutations (percentages are shown) in the coding sequence after SaCas9-KKH + gRNA 4.2 transfection. g, GUIDE-Seq analysis on SaCas9-KKH + gRNA 4.2 transfected Tmc1
Bth/WT fibroblasts. Genomic DNA was pooled from three biological replicates for sequencing on one occasion. The number next to read is read count in the GUIDE-Seq assay.
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indel rates in no-gRNA control samples, which likely reflect PCR/ sequencing error (Extended Data Fig. 4) . Importantly, SaCas9-KKH + gRNA 4.2 was specific for the Tmc1 Bth allele; we did not detect cleavage at any genome-wide off-target sites using GUIDESeq (genome-wide unbiased identification of double-strand breaks enabled by sequencing) (Fig. 1g) .
SaCas9-KKH and gRNA 4.2 were packaged into Anc80L65 capsids 17 ( Fig. 2a) for delivery to sensory hair cells of the cochlea. One microliter of virus was injected into the inner ears of postnatal day (P) 1 mice (Fig. 2b) . We performed targeted deep sequencing from whole cochlear tissue at different ages post-injection and in noninjected animals (Fig. 2c) . In whole cochlea, in which supporting cells vastly outnumber viral-targeted hair cells, we observed 0.2%, 1.8%, 1.6% and 2.2% indel frequencies at 7, 14, 42 and 55 d after injection, respectively. Indel formation in injected WT animals was not different from background even after 196 d ( Fig. 2c; Bth/WT animals ( Fig. 2d,e) . Next, we used a more sensitive, independent analysis-the presence of AAV-inverted terminal repeats in the cut site 18 -to investigate allele selectivity of SaCas9-KKH. In non-injected Tmc1
Bth/WT animals, we did not detect AAV reads within the Tmc1 gene ( Fig. 2f ) but AAV integration was evident in the Tmc1
Bth allele in all injected animals at P42 or P55. However, we found only three unique Tmc1
WT reads with AAV integration in 45 injected mice, corresponding to a 0.0075% indel rate (Supplementary Note 1), suggesting little SaCas9-KKH activity on the WT allele. As a final test, we analyzed gene editing at the messenger RNA level. In contrast to non-injected Tmc1
Bth/WT animals, we observed some indel formation at the mRNA level in injected animals at P55 (0.83% in injected animals, Fig. 2g ), but only in mutant alleles. We also observed a 24% decrease (Fig. 2h ) in non-modified Bth mRNA relative to non-modified WT mRNA in injected animals (Supplementary Note 2).
Next, we investigated whether the consequences of SaCas9-KKH-mediated disruption of the Bth allele could be detected in hair-cell mechanosensory transduction currents. Although the Bth mutation eventually causes cell death, the mutation does not cause a loss of mechanosensitivity 19 . Single-cell electrophysiology was performed on hair cells from either Tmc1 WT/WT or Tmc1 Bth/Δ mouse pups on a Tmc2 Δ/Δ background because Tmc2 contributes to mechanosensory currents and is expressed transiently at neonatal stages 20 . After injection of AAV-SaCas9-KKH-gRNA-4.2 at P1, cochleas were dissected at P5-P7 and cultured for 8-10 d, or the equivalent of P14-P16. Both inner (IHCs) and outer hair cells (OHCs) from injected Tmc1 WT/WT mice showed normal current amplitudes (Extended Data  Fig. 5a,b ;Tmc2 Δ/Δ mice, in some cases almost completely abolishing the current (Fig. 3a,b) .
We next measured auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAE) in Bth mice using our allele-specific SaCas9-KKH nuclease (Fig. 2b) . In 8-week-old Tmc1
Bth/WT mice, ABR recordings revealed elevated hearing thresholds (90 dB at 8 kHz; Bth/WT animals injected with AAV-SaCas9-KKH-gRNA-4.2, we observed improved thresholds at 8 weeks (45 dB median threshold; Fig. 3c,d ). At 4 weeks, the mice with the greatest hearing preservation had ABR thresholds of 20-35 dB in the 5-16 kHz test range, indistinguishable from WT mice (Fig. 3d) .
Since the Bth mutation causes progressive hearing loss, we measured the time course of hearing sensitivity in Tmc1
Bth/WT and Tmc1 WT/WT animals 4, 8, 12 and 24 weeks after injection at frequencies from 5.6 to 32 kHz (Fig. 3d,f and Extended Data Fig. 5d,e) . At 4 weeks of age, uninjected Bth mice had low-frequency hearing but high-frequency hearing loss (Fig. 3d ), similar to previous reports 5, 16 . At later time points, ABR thresholds were progressively elevated and at 24 weeks of age no ABR thresholds were detected in untreated Bth mice (Extended Data Fig. 5e ). In contrast, Bth mice injected with AAV-SaCas9-KKH-gRNA-4.2 showed normal or near-normal ABR thresholds at low frequencies (8 kHz; injected, 38 ± 11 dB, n = 9; uninjected, 64 ± 19 dB, n = 8), and improved, but not completely normalized, ABR thresholds at high frequencies (22 kHz; injected, 84 ± 15 dB, n = 9; uninjected, 103 ± 5 dB, n = 8). In contrast to uninjected Bth mice, ABR thresholds in injected mice did not deteriorate over time (8 kHz; 8 weeks, 45 ± 15 dB, n = 9; 12 weeks, 48 ± 17 dB, n = 10; 24 weeks, 40 ± 7 dB, n = 4; Fig. 3f ). At 24 weeks, injected mice exhibited normal or near-normal thresholds at 5-8 kHz, while untreated animals were profoundly deaf. One injected animal showed remarkable preservation of hearing even in high frequencies at 24 weeks of age (Extended Data Fig. 5e ).
ABR peak 1 (P1) amplitudes were in the normal range for most of the injected Bth mice at 8 weeks, in contrast to non-injected animals, which showed small P1 amplitudes only at high sound intensities (Extended Data Fig. 6a ). Latencies of P1 waves of injected Tmc1
Bth/WT animals were also normalized by injection (Extended Data Fig. 6b ). To test OHC function, we performed DPOAE measurements at 4, 8, 12 and 24 weeks after injection. Like the ABRs, DPOAE thresholds in injected Bth mice revealed preservation of OHC function at lower frequencies (5-11 kHz) at 12 weeks of age ( Fig. 3e ) and in the surviving animals up to 24 weeks of age. We also investigated whether AAV-SaCas9-KKH-gRNA-4.2 injection disrupts hearing in WT animals. We performed ABRs and observed no ABR or DPOAE threshold shifts, even 24 weeks post-injection (Extended Data Fig. 5d, 8 kHz; injected, 38 ± 8 dB, n = 3; uninjected, 38 ± 6 dB, n = 6) confirming that AAV-SaCas9-KKH does not disrupt hearing function in Tmc1 WT/WT mice. In one cohort of four Bth mice we measured ABR thresholds 40 weeks post-injection. We tracked thresholds (8 kHz) between 4 and 40 weeks and excluded data from two mice with failed injections, based on histological examination (see next paragraph). Thresholds were stable over time and only slightly elevated relative to WT mice (Fig. 3f) . Two of six mice that survived to 1 year of age had stable ABR thresholds of 35 and 40 dB at 8 kHz.
Next, we evaluated hair cell survival in injected and non-injected Tmc1
Bth/WT and Tmc1 WT/WT animals. Following ABR and DPOAE evaluations, mice were sacrificed at 24 weeks of age. Surviving hair cells were identified with an antibody for MYO7A and phalloidin staining for actin. IHCs and OHCs were present in uninjected Tmc1
WT/WT mice and those injected with AAV-SaCas9-KKH-gRNA-4.2 (Extended Data Fig. 5f,g ). In contrast, uninjected Tmc1
Bth/WT animals showed significant hair cell loss in all regions (Fig. 3g,h ). In the low-frequency (8 kHz) apex, many hair cells were missing, and in the 16 and 32 kHz regions, essentially all hair cells were absent.
In contrast, injected Tmc1
Bth/WT animals showed normal sensory epithelia in the 8 and 16 kHz regions (Fig. 3g,h) , with minimal hair cell loss. In the basal region (32 kHz) IHCs survived, but not OHCs (Fig. 3g,h ). We also found that mean ABR thresholds were correlated with the percentage of surviving hair cells at the low-frequency end of the cochlea (Extended Data Fig. 6c ).
Hair bundle morphology was evaluated with scanning electron microscopy (SEM) in Bth and WT hair cells. In uninjected Tmc1 WT/ WT animals at 24 weeks of age, IHC and OHC showed classical staircase organization of hair bundles (Fig. 3i) . In contrast, surviving hair cells from Tmc1
Bth/WT animals showed significant bundle disorganization. Hair cells from AAV-SaCas9-KKH-gRNA-4.2-injected mice, however, showed preservation of normal hair bundle morphology in both IHCs and OHCs (Fig. 3i) . These results are concordant with the ABR data, which showed robust preservation of Table 6 includes the number of cochleas at each data point; number of independent sequencing reactions for non-injected animals, 5 (P7), 2 (P14), 2 (P27); injected, 5 (P7), 2 (P14), 2 (P42), 2 (P55) and 2 (P196 WT)). ANOVA was performed to describe overall difference (F = 445.8, P < 0.0001) followed by Tukey's post-hoc test (for statistical results see Supplementary Bth/WT animals at P14-P55. Mean ± s.d., number of independent experiments and sequencing reactions, 2 for non-injected and 6 for injected). Supplementary Table 6 includes the age and number of cochleas for each data point. g, Indel profiles and read abundance at the mRNA level from AAV-SaCas9-KKH-gRNA-4.2 injected Tmc1
Bth/WT animals. Data representation is similar to Extended Data Fig. 1f . h, Relative read counts for Tmc1
Bth and Tmc1 WT representing mRNA in non-injected and injected animals (Supplementary Table 6 includes age and number of cochleas for each data point). The dashed line represents an equal ratio (ratio = 1). (ANOVA, P = 0.0001, Dunnett's multiple comparisons: P = 0.0005 for injected (P42) versus non-injected (P42) and P = 0.0001 for injected (P55) versus non-injected (P42)). ; OHCs, 71 ± 41 pA, n = 12, P = 8.1 × 10 
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To validate our strategy for targeting the human p.M418K mutation, we created a haploid human cell line containing the p.M418K mutation in TMC1 (c.T1253A). TMC1 DFNA36 and TMC1 WT cells were transfected with SaCas9-KKH and three different gRNAs targeting the mutant allele (Fig. 4a) . Transfection efficiency was similar between the two lines (Extended Data Fig. 7) . Targeted deep sequencing of TMC1 revealed indel formation in the TMC1 DFNA36 line, but no indel formation in the TMC WT line (Fig. 4b and Extended Data Fig. 8) , suggesting specific disruption of the mutant allele. The most common indel event was a single nucleotide deletion but we also observed larger deletions (Fig. 4c) . These results suggest that our strategy translates to human cells and that allele-specific targeting of dominant mutations holds promise for preventing dominant hearing loss. In addition to the TMC1 p.M418K mutation (DFNA36), we identified 15 other dominant mutations in deafness genes potentially targetable with SaCas9-KKH (Fig. 4d and Supplementary Table 2 ). To further generalize our results, we analyzed all known dominant human mutations for possible specific PAM targeting using SaCas9 and SaCas9-KKH. SaCas9 has a unique PAM requirement of 'GRRT' , while SaCas9-KKH has a PAM requirement only of 'RRT' . Of 17,783 dominant entries (Supplementary Table 3 ) in the ClinVar database (see Supplementary Note 3), the SaCas9 GRRT PAM site was evident in 1,328 variants (7.5%) (Supplementary Table 4 and Fig. 4d ), while the SaCas9-KKH PAM site may be able to distinguish mutant from WT for 3,759 dominant alleles (21.1%) (Supplementary Table 5 and Fig. 4d ).
For the current study we screened multiple gene editing strategies for specific disruption of the Beethoven mutation in Tmc1, a gene critical for auditory function 6 . We compared gRNAs with different PAM locations, truncated gRNAs, high-fidelity Cas9 enzymes and a SaCas9 variant characterized by an NNNRRT PAM site 11 . All gRNAs with SpCas9 of high-fidelity Cas9 enzymes had significant activity at the WT allele, suggesting that selective single-base discrimination cannot be achieved with gRNAs targeting the Bth allele. In contrast, targeting the mutation with SaCas9-KKH led to undetectable WT allele disruption, suggesting that the wild-type T was not tolerated by this PAM-variant enzyme.
Our results represent a significant improvement over previous strategies, where hearing preservation was modest and not sustained even at low frequencies 16, 22, 23 . In the Gao et al. study 16 , the limited durability may have been due to an insufficient number of transfected hair cells with lipid-mediated Cas9/gRNA delivery; the subsequent cell death may have resulted from non-cell autonomous factors, as described for genetic mutations that affect the retina 24 .
Another possibility is that lack of specificity 16 led to cumulative inactivation of the WT allele. With our approach, AAV-mediated SaCas9-KKH delivery durably improved hearing preservation out to 1 year of age with no toxicity. We did not detect indel formation or elevated hearing thresholds in WT mice even 196 d after SaCas9-KKH injection. Furthermore, we did not detect off-target effects in cultures of primary fibroblasts with SaCas9-KKH + gRNA 4.2 despite the high level of on-target activity. Importantly, the human TMC1 mutation described by Zhao et al. 15 (p.M418K, c.T1253A) is also amenable to allele-specific SaCas9-KKH gene disruption. In human HAP1 cells, indel formation was only observed in the mutant TMC1 p.M418K allele, but not the WT allele.
While this study focuses on a single missense mutation observed in relatively few hearing loss patients, our ClinVar database analysis revealed that 3,759 dominant disease variants (Supplementary Note 3) are potentially amenable to SaCas9-KKH disruption, which contrasts with S. aureus Cas9
WT with 1,328 potential targets. Thus, our PAM-selective strategy has potential broad application, as roughly one-quarter of all dominant human mutations may be amenable to allele-specific disruption with SaCas9-KKH, suggesting a precision approach for selective silencing of thousands of human disease genes.
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Bth allele and differed in their length and distance between the mutation and PAM site. For gRNAs 1.1-1.4 and 2.1-2.4, we took advantage of a PAM site adjacent to the mutation. Our gRNA 1.1 is identical to the Tmc1-mut3 gRNA in the study by Gao et al. 16 . In the case of gRNAs 3.1-3.3 we used an AAG PAM site created by the mutation in order to recognize the mutant allele specifically, as it has been shown that SpCas9 can also cleave at NAG PAM sites with somewhat lower efficiency 3 . We also used several truncated gRNAs because previous studies reported enhanced specificity 7 . We synthesized one gRNA specific for the Tmc1 WT allele as a control. We used gRNA 1.1 (Extended Data Fig. 1a ) in combination with eSpCas9(1.1) 10 , HypaCas9 (ref.
9
) or SpCas9-HF1 (ref. 8 ; Fig. 1a) . We did not use gRNA 2.4 in these experiments, as it has been shown that truncated gRNAs substantially decrease on-target activity of high-fidelity Cas9 enzymes 8 . pBG201 (AAV-CMV-NLS(SV40)-SaCas9 (E782K/N968K/R1015H)-NLS(nucleoplasmin)-3xHA-bGHpA0-U6-BsaI-sgRNA) was created by synthesizing a gene fragment of the SaCas9-KKH and cloning into the pX601 (ref. 25 ) backbone using FseI (NEB) and CsiI (Thermo Scientific). Whole plasmid sequencing (MGH DNA Core) was used to verify the sequence of pBG201 (Supplementary Data Set 4). To clone gRNAs into pX458, MLM3636 and pBG201 we used Fast Digest BpiI (Thermo Scientific), BsmbI (NEB) and BsaI, respectively. We used three different gRNAs (4.1, 4.2 and 4.3) with SaCas9-KKH (Fig. 1a) . The correct gRNA inserts were sequenced using a U6 sequencing primer: 5′-GACTATCATATGCTTACCGT-3′.
Cell culture, transfection and sorting. Mouse primary dermal fibroblasts were established from neonatal C57BL/6 Tmc1
WT/WT and Tmc1 Bth/WT animals. Briefly, after euthanasia, a small amount of skin was dissected into small pieces and washed with PBS. Next, cells were treated at 37 °C with 1 mg ml -1 collagenase I (Worthington) for 30 min followed by 0.05%-trypsin-EDTA treatment for 15 min. Cells were cultured in 10% fetal bovine serum containing DMEM (Gibco) supplemented with 1x penicillin/streptomycin (Gibco). Cell lines were validated by Sanger sequencing. Mycoplasma screening (MycoAlert, Lonza) was performed regularly and before transfection experiments. For transfection of fibroblasts, we used Nucleofection (Lonza) (CZ-167 program, P2 Primary Cell 4D-Nucleofector X Kit). Every transfection reaction was performed in duplicate and experiments were performed on at least two separate occasions. Four days after transfection of pX458 plasmids, cells were sorted based on green fluorescent protein (GFP) fluorescence using a FACS Aria Cell Sorter (BD), and genomic DNA was isolated and analyzed by Sanger sequencing and targeted deep sequencing. In the case of high-fidelity SpCas9s (eSpCas9(1.1), HypaCas9, SpCas9-HF1) and SaCas9-KKH transfections, cells were not sorted, but genomic DNA was isolated from all cells 4 d after transfection for deepsequencing analysis.
Mouse genomic DNA isolation and PCR. Genomic DNA was isolated from fibroblasts 4 d after transfection using a Qiagen Blood and Tissue Kit (Qiagen). In the case of cochlear tissue, organs were harvested at different ages (Fig. 2c) and dissociated with 1× collagenase I/5× dispase (Gibco) for 40 min in Cell Dissociation Buffer (Gibco), as described previously 26 . Organs were further dissociated by passing through a 20 G needle ten times. DNA and RNA from cochlear tissue were isolated using a Qiagen AllPrep DNA/RNA micro kit. To amplify the Tmc1 gene, we used the following primers: 5′-TAAAGGGACCGCTCTGAAAA-3′ (forward) and 5′-CCATCAAGGCGAGAATGAAT-3′ (reverse). To amplify the Tmc1 message, we used 5′-CCATCAAGGCGAGAATGAAT-3′ (forward) and 5′-ACCTCATCTTTTGGGCTGTG-3′ (reverse). PCR products were visualized on a 1% agarose gel using GelRed (Thermo Fisher) and purified on a column (PCR Purification Kit, Qiagen). For Sanger sequencing, we used 200-500 ng of genomic DNA and for targeted deep sequencing we used 500-1400 ng of genomic DNA. Sequencing was performed at the MGH DNA Core (Sanger-sequencing and CRISPR-sequencing service). Paired-end reads (150 base pairs) were generated on an Illumina MiSeq platform with a 100K read depth per sample (Extended Data Fig. 9 ).
Sanger sequencing and TIDE analysis. Sanger sequencing was performed in the MGH DNA Core. Sequence traces were analyzed by deconvolution (TIDE, Tracking Indels by Decomposition, Desktop Genetics). Aberrant sequences were quantified downstream of the CRISPR cut site. Analysis was performed on forward and reverse traces and gene editing efficiency was averaged.
Targeted deep-sequencing data analysis. CRISPR-induced indels were analyzed by CRISPResso using two separate methods (Extended Data Fig. 9 ). During quantification, we ignored substitutions (only insertions and deletions were quantified) and indels outside of a 10 base-pair window of the CRISPR cut site were disregarded.
Global CRISPResso indel analysis. To analyze CRISPR action on both Tmc1
Bth and Tmc1
WT alleles, we subjected the fastq files to CRISPResso analysis without segregating them to mutant and WT reads (Extended Data Fig. 9b) . Briefly, reads were split to read 1 and read 2, then merged using flash v.1.2.11 (parameters: min overlap, 4; max overlap, 126; max mismatch density, 0.250000; allow 'outie' pairs, true; cap mismatch quals, false; combiner threads, 8; input format, fastq; phred_ offset = 33; output format, fastq; phred_offset = 33). Next, CRISPResso was run with the following parameters: CRISPResso -r1<fastq_file>-split_paired_end -w 5 -c<protein_coding_sequence>-ignore_substitutions -a<amplicon_sequence>-g<gRNA_sequence>.
Allele-specific CRISPResso indel analysis. To analyze CRISPR action on Tmc1
WT alleles separately, we first split fastq files to read 1 and read 2, then we merged them using flash v.1.2.11, as described in the above section. The reads from heterozygous samples were segregated based on the presence of WT sequence ('TGGGACAGAACA' and its reverse complement 'TGTTCTGTCCCA') and mutant sequence ('TGGGACAGAACT' and its reverse complement ' AGTTCTGTCCCA'; mutation site is underlined) using a custom Python script (v.3.4.2) used previously 27 . Reads were segregated based on a sequence downstream of the projected CRISPR cut site so that indels have minor influence on the segregation (Extended Data Fig. 9c ). After segregation, CRISPResso was run separately on Tmc1
Bth and Tmc1 WT reads with the following paramters: -r1<fastq_ file>-w 5 -c<protein_coding_sequence>-ignore_substitutions -a<amplicon_ sequence>-g<gRNA_sequence>.
For mRNA analysis, we first merged the reads with flash as described in the above section. CRISPResso analysis was performed similarly to global indel analysis. To quantify intact, non-edited reads, we used the following sequences: 5′-CATCCCCAGGAGGG-3′ and 5′-CCCTCCTGGGGATG-3′ for WT reads, and 5′-CTTCCCCAGGAGGG-3′ and 5′-CCCTCCTGGGGAAG-3′ for mutant reads.
Off-target analysis. To detect genome-wide Cas9 nuclease activity, a GUIDE-Seq assay was performed in fibroblasts 3 . Briefly, 2 μg of Cas9-2A-GFP-U6-gRNA-2.4 or 2 μg of AAV-CMV-SaCas9-KKH-U6-gRNA-4.2 along with 50 pmol annealed GUIDE-Seq oligo (forward: /5Phos/G*T*TTAATTGAGTTGTCATATGTTAATA ACGGT*A*T, reverse: /5Phos/A*T*ACCGTTATTAACATATGACAACTCAATT AA*A*C, stars indicate thioate bonds) were transfected into Tmc1
Bth/WT fibroblasts using electroporation (see above). Four days after transfection, genomic DNA was isolated with a Qiagen DNA Blood and Tissue kit, and a library was constructed as described previously 3 . Sequencing was performed on an Illumina MiSeq machine. As a control, GUIDE-Seq oligo was transfected without CRISPR/Cas9 plasmids. GUIDE-Seq data were analyzed with the guideseq pipeline v.1.1b4 (https://github. com/aryeelab/guideseq) using mm10 as the reference mouse genome.
AAV vector production. AAV vectors were produced by the Boston Children's Hospital Viral Core (Boston, MA, USA). Plasmid containing SaCas9-KKH and gRNA 4.2 was sequenced before packaging (MGH DNA Core, complete plasmid sequencing, Supplementary Data Set 4) into AAV2/Anc80 (ref. 28 ). Vector titer was 4.8 × 10 14 genome copies ml -1 as determined by qPCR specific for the inverted terminal repeat of the virus.
Inner-ear injections. Inner ears of Tmc1
Bth/WT or Tmc1 WT//WT mouse pups were injected at P1 with 1 μl of Anc80-AAV-CMV-SaCas9-KKH-U6-gRNA-4.2 virus at a rate of 60 nl min -1 . Pups were anesthetized using hypothermia exposure in ice water for 2-3 min. Upon anesthesia, a post-auricular incision was made to expose the otic bulla and visualize the cochlea. Injections were made manually with a glass micropipette. After injection, a suture was used to close the skin cut. Then, the injected mice were placed on a 42 °C heating pad for recovery. Pups were returned to the mother after they fully recovered within ~10 min. Standard post-operative care was applied after surgery. Sample sizes for in vivo studies were determined on a continuing basis to optimize the sample size and decrease the variance. At P5 to P7, organs of Corti were excised from injected ears. Organ of Corti tissues were incubated at 37 °C, 5% CO 2 for 8-10 d, and the tectorial membrane was removed right before electrophysiology recording.
Hair cell electrophysiology. Mechanotransduction currents were recorded from cochlear IHCs and OHCs at P14-P16. Organ of Corti tissues were bathed in external solution containing (in mM) 140 NaCl, 5.8 KCl, 0.7 NaH 2 PO 4 , 10 HEPES, 1.3 CaCl 2 , 0.9 MgCl 2 , and 5.6 glucose, and vitamins and essential amino acids (Thermo Fisher Scientific), adjusted to pH 7.4 with NaOH, ~310 mmol kg 
Data were low-pass filtered at 5 kHz (Bessel filter) and then sampled at 20 kHz with a 16-bit acquisition board (Digidata 1440A). Data were corrected for a −4 mV liquid junction potential in standard extracellular solutions. Cochlea IHC and OHC bundles were deflected using stiff glass probes mounted on a PICMA chip piezo actuator (Physik Instruments) driven by an LPZT amplifier (Physik Instruments) and filtered with an 8-pole Bessel filter at 40 kHz to eliminate residual pipette resonance. Fire-polished stimulus pipettes with 3-5 µm tip diameter were designed to fit into the concave aspect of the hair cell bundle, as previously described 29 . Hair bundle deflections were monitored using a C2400 CCD camera (Hamamatsu).
Hearing tests. ABR and DPOAE measurements were recorded using the EPL Acoustic System (Massachusetts Eye and Ear (MEE)). Stimuli were generated with 24-bit digital input/output cards (PXI-4461 National Instruments) in a PXI-1042Q chassis, amplified by a SA-1 speaker driver (Tucker-Davis Technologies, Inc.), and delivered from two electrostatic drivers (CUI CDMG15008-03A) in our custom acoustic system. An electret microphone (Knowles FG-23329-P07) at the end of a small probe tube was used to monitor ear-canal sound pressure. ABRs and DPOAEs were recorded from mice during the same session. Mice were anesthetized with intraperitoneal injection of xylazine (5-10 mg kg -1 ) and ketamine (60-100 mg kg -1 ) and the base of the pinna was trimmed away to expose the ear canal. Three subcutaneous needle electrodes were inserted into the skin, including (1) dorsally between the two ears (reference electrode), (2) behind the left pinna (recording electrode) and (3) dorsally at the rump of the animal (ground electrode). Additional aliquots of ketamine (60-100 mg kg -1 intraperitoneal) were given throughout the session to maintain anesthesia if needed. DPOAEs were recorded first. The f1 and f2 primary tones (f2/f1 = 1.2) were presented with f2 varied between 5.6 and 32.0 kHz in half-octave steps and L1−L2 = 10 decibel sound pressure level (dB SPL). At each f2, L2 was varied between 10 and 80 dB in 10 dB increments. DPOAE threshold was defined from the average spectra as the L2-level eliciting a DPOAE of magnitude 5 dB above the noise floor. The mean noise floor level was under 0 dB across all frequencies. ABR recordings were then recorded, with stimuli of broadband 'click' tones as well as the pure tones between 5.6 and 32.0 kHz in half-octave steps, all presented as 5-ms tone pips. The responses were amplified (10,000 times), filtered (0.1-3 kHz) and averaged with an analog-to-digital board in a PC-based data-acquisition system (EPL, Cochlear function test suite, MEE). Across various trials, the sound level was raised in 5 to 10 dB steps from 0 to 110 dB SPL. At each level, 512 responses were averaged (with stimulus polarity alternated) after 'artifact rejection' . Threshold was determined by visual inspection of the appearance of P1 relative to background noise. Data were analyzed and plotted using Origin-2015 (OriginLab Corporation). Threshold averages ± standard deviations are presented unless otherwise stated. The majority of these experiments were not performed under blind conditions. Confocal microscopy. The temporal bones of 24-week-old adult mice were harvested, cleaned and placed in 4% formaldehyde for 1 h, followed by decalcification for 24-36 h with 120 mM EDTA (pH = 7.4). The sensory epithelium was then dissected and remained in PBS until staining. Tissues were permeabilized with 0.01% Triton X-100 for 1 h, blocked with 2.5% normal donkey serum and 2.5% BSA in 0.01% Triton X-100 for 1 h, and then incubated with anti-MYO7A primary antibody (Proteus Biosciences) overnight (1:500 dilution). Tissues were then washed and counterstained with phalloidin for 2-3 h. Images were acquired on a Zeiss LSM 800 laser confocal microscope. Full cochlear maps were reconstructed in Adobe Photoshop and tonotopically mapped using an ImageJ plugin.
Scanning electron microscopy. The temporal bones of 24-week-old adult mice were harvested, and cleaned temporal bones were placed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (EMS) supplemented with 2 mM CaCl 2 for 45 min. Wholemount tissues were dissected in distilled water and then dehydrated over the course of 4 h to pure ethanol. Tissues were critical-point dried (Autosamdri-815, series A, Tousimis) and mounted on carbon tape attached to SEM specimen stubs. The mounted tissues were coated with 4 nm of platinum (Leica EM ACE600) and then imaged at 5 kV with a scanning electron microscope (Hitachi S-4700 FESEM).
ClinVar database analysis. The ClinVar database from 25 March 2019 was downloaded from ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh38/ archive_2.0/2019/clinvar_20190325.vcf.gz. The database was filtered for 'dominant' diseases, resulting in 17,783 entries. The possibility of generating a PAM site from single nucleotide mutations was analyzed for the SaCas9 (GRRT) and SaCas9-KKH (RRT) recognition motifs. The GRCh38 human reference genome was queried for 7-nt or 5-nt sequences surrounding the site of interest, that is, 3 (GRRT) or 2 (RRT) nucleotides on either side of the mutation. These sequences were analyzed with a sliding window of length 4 (GRRT) or 3 (RRT) nucleotides. Entries that had a putative PAM site in both the 'variant' nucleotide string and the 'reference' (WT) string were excluded from further analysis. The same procedure was used for the reverse complement strand. The resulting databases (all dominant entries, dominant entries with PAM site formation for SaCas9 and dominant entries with PAM site formation for SaCas9-KKH recognition) are uploaded as Supplementary Tables 3-5 . We also analyzed all ClinVar entries without filtering from dominant diseases. This analysis was done, as several dominant variants are not annotated as 'dominant' in the ClinVar database. This data set is presented as Supplementary Table 9 (variants targetable with SaCas9-WT) and Supplementary Data Set 10 (variants targetable with SaCas9-KKH).
TMC1 gene inactivation in human haploid cells. A human cell line carrying the equivalent of the Beethoven mutation in the human TMC1 gene (ATG to AAG mutation, encoding the M418K amino acid substitution) was engineered from the HAP1 parental cell line derived from the KBM-7 haploid cells (Horizon Genomics GmbH) 30 . Briefly, a T to A point mutation was introduced in the exon 16 of the TMC1 gene (ENSG00000165091; genomic location: chr9: 72,791,914) to generate the TCCCTCCTAGGGAAGTTC sequence. For insertion of the mutation by gene editing, the HAP1 cell line was modified with the CRISPR/Cas9 nuclease using two gRNA sequences (5′-CATCGCTTTGAAATGGCTAC-3′ and 5′-AACCATGTTCATCTACAAGG-3′) and a 1 kb donor template encompassing TMC1 exon 6 and which contained the T to A Beethoven mutation. The genetic identity of the cells was verified by Sanger sequencing of a PCR amplicon.
The parental and HAP1 cell lines were cultured as monolayer at 37 °C in a humidified atmosphere with 5% CO 2 , using IMDM medium plus GlutaMAX (Gibco) supplemented with 10% FBS, 100 U ml -1 penicillin and 100 µg ml -1 streptomycin. Cells were passaged every 2-3 d when reaching 70-75% confluency. For transfection, the cells were grown in six-well plates at a 70% confluency. One day later, cells were transfected with 2.5 µg of plasma DNA using Lipofectamine 3000 (Thermo Fisher), following manufacturer's instructions. Two days after transfection, the cells were collected by trypsinization and the pellet was stored at −20 °C. Total genomic DNA was extracted from the cells with the NucleoSpin Tissue kit (Macherey-Nagel AG). A PCR amplicon was amplified for next-generation sequencing, using the Phusion High-Fidelity DNA Polymerase (Thermo Fisher).
For TMC1 DFNA36 cells we used the primers 5′-AGCCTAGCTCAGAATCTTCCA-3′ and 5′-AAAATGCGTCCCAGTAGCCA-3′. For TMC WT cells we used the 5′-AAAATGCGTCCAAGTAGCCA-3′ due to a point mutation in the primer binding region. The PCR protocol was based on manufacturer's instruction, with 35 cycles (5 s at 98°C; 20 s at 59°C; 15 s at 72 °C). The PCR product was visualized on a 2% agarose gel and purified with the PCR clean-up and gel extraction kit (Macherey-Nagel AG). Next-generation sequencing was performed by the Massachusetts General Hospital DNA Core facility.
To verify transfection efficacy in each sample, we quantified by TaqMan real-time PCR the number of plasmid copies of the sequence contained in the AAV inverted terminal repeats using the following primers: forward, 5′-GGAACCCCTAGTGATGGAGTT-3′; reverse, 5′-CGGCCTCAGTGAGCGA-3′; probe, 5′-FAM-CACTCCCTCTCTGCGCGCTCG-BHQ1-3′. The amount of cellular gDNA was quantified using a set of primers specific for the human albumin gene: forward, 5′-TGAAACATACGTTCCCAAAGAGTTT-3′; reverse, 5′-CTCTCCTTCTCAGAAAGTGTGCATAT-3′; probe, 5′-FAM-TGCTGAAACATTCACCTTCCATGCAGA-BHQ1-3′. Absolute numbers of copies were determined according to standards and used to calculate the number of plasmid copies per cell.
Statistical analysis. We used GraphPad Prism v.7.0 for Mac OS and OriginPro (2015) for statistical analysis. To compare means, we used an unpaired two-tailed t-test (after Shapiro-Wilk normality testing); to compare multiple groups, we used analysis of variance (ANOVA) followed by Tukey's post-hoc test (to compare every mean to every other mean) or Dunnett's test (to compare every mean to a control group mean). P values < 0.05 were accepted as significant.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article. . 1b) . Note that data points show non-normalized read counts. Cells were transfected on two different occasions (SpCas9 only and SpCas9 + gRNA 1.1 on four occasions) and genomic DNA from two independent biological samples on each transfection day were pooled for sequencing. Indels in the SaCas9-KKH treated Tmc1 WT/WT lines are not different from the background (untreated samples). This method revealed high sensitivity, as the indel rates in CRISPR treated samples were 40-160-fold higher than the background indel rates observed in untreated samples. WT/WT mice (black, n = 6) and three Tmc1 WT/WT mice injected with AAV-SaCas9-KKH-gRNA-4.2 (gray) at 24 weeks of age (P = 0.9). e, Mean ± s.d. ABR thresholds plotted as a function of stimulus frequency for six Tmc1 WT/WT mice (black), nine Tmc1 Bth/WT and five Tmc1 Bth/WT mice injected with AAV-SaCas9-KKH-gRNA-4.2 (green) at 24 weeks of age. 8 kHz thresholds for injected, 38 ± 11 dB (n = 9) and uninjected, 64 ± 19 dB (n = 8) were significantly different (P = 0.004, unpaired two-tailed t-test). ABR thresholds at higher frequencies (22 kHz) for injected (84 ± 15 dB, n = 9) and uninjected Tmc1
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Bth/WT mice (103 ± 5 dB, n = 8; P = 0.004, unpaired two-tailed t-test). f, Representative confocal images of 100-µm cochlear sections harvested at 24 weeks from the 8, 16 and 32 kHz regions from three uninjected Tmc1 WT/WT mice (top) and three Tmc1 WT/WT mice injected with AAV-SaCas9-KKH-gRNA-4.2 (bottom). The tissue was stained for MYO7A (red) and actin (green). g, Mean ± s.d., number of surviving IHCs (left) and OHCs (right) per 100-µm section (n = 3). 
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